Compositions and methods for treating retroviral infections
AssigneeSurrogate Pharmaceutical Pathways, LLC
InventorDamian J. Gallina
Life of this patent
Estimating the term…
Abstract
The present invention relates to hyaluronidase enzyme methods, vaccines and compositions for treating or preventing pathogenic infections, such as HIV, in a patient. The invention also relates to methods, vaccines and compositions for providing immunity against HIV infection in a patient comprising treating the patient with HIV virus or HIV infected cells that have been treated with hyaluronidase.
Claims24
A pharmaceutical composition for preventing or treating an HIV infection in a patient comprising a hyaluronidase enzyme.
A pharmaceutical composition for preventing or treating an HIV infection in a mammal comprising a hyaluronidase treated HIV virus.
A pharmaceutical composition for preventing or treating an HIV infection in a mammal comprising an anti-HIV infection amount of antigen presenting cells that have been sensitized with hyaluronidase treated HIV infected cells.
A pharmaceutical composition for preventing or treating an HIV infection in a mammal comprising an anti-HIV infection amount of antigen presenting cells that have been sensitized with hyaluronidase treated HIV virus.
An anti-HIV vaccine comprising a hyaluronidase treated HIV virus.
A method of inducing or enhancing immunity in a patient in need of such treatment in order to initiate responses to otherwise self or host lineage altered cells, antigens or immunogens the method comprising administering to said patient a hyaluronidase enzyme.
A pharmaceutical composition used to initiate immune responses to pathogens or pathogen infected cells in a patient in need of such treatment comprising a hyaluronidase enzyme.
Dependencies are inferred from the claim text.